These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 17077189)

  • 1. Studies on the physiological functions of the melanocortin system.
    Cone RD
    Endocr Rev; 2006 Dec; 27(7):736-49. PubMed ID: 17077189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanocortin receptors: their functions and regulation by physiological agonists and antagonists.
    Abdel-Malek ZA
    Cell Mol Life Sci; 2001 Mar; 58(3):434-41. PubMed ID: 11315190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanocortins and their receptors and antagonists.
    Voisey J; Carroll L; van Daal A
    Curr Drug Targets; 2003 Oct; 4(7):586-97. PubMed ID: 14535656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of endogenous and synthetic melanocortin peptides.
    Wilson KR; Todorovic A; Proneth B; Haskell-Luevano C
    Cell Mol Biol (Noisy-le-grand); 2006 May; 52(2):3-20. PubMed ID: 16914082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New ligands for melanocortin receptors.
    Kaelin CB; Candille SI; Yu B; Jackson P; Thompson DA; Nix MA; Binkley J; Millhauser GL; Barsh GS
    Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S19-27. PubMed ID: 19136986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of the unique and potent agouti-related protein (AGRP)-melanocortin chimeric Tyr-c[beta-Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH2 peptide template.
    Wilczynski A; Wilson KR; Scott JW; Edison AS; Haskell-Luevano C
    J Med Chem; 2005 Apr; 48(8):3060-75. PubMed ID: 15828845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Melanocortin system].
    Levitskaia NG; Kamenskiĭ AA
    Usp Fiziol Nauk; 2009; 40(1):44-65. PubMed ID: 19326848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors.
    Kiefer LL; Ittoop OR; Bunce K; Truesdale AT; Willard DH; Nichols JS; Blanchard SG; Mountjoy K; Chen WJ; Wilkison WO
    Biochemistry; 1997 Feb; 36(8):2084-90. PubMed ID: 9047307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agouti antagonism of melanocortin-4 receptor: greater effect with desacetyl-alpha-melanocyte-stimulating hormone (MSH) than with alpha-MSH.
    Mountjoy KG; Willard DH; Wilkison WO
    Endocrinology; 1999 May; 140(5):2167-72. PubMed ID: 10218968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive receptor activity series: endogenous inverse agonists and constitutive receptor activity in the melanocortin system.
    Adan RA
    Trends Pharmacol Sci; 2006 Apr; 27(4):183-6. PubMed ID: 16500715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Agouti-related protein binding to melanocortin receptors.
    Yang YK; Thompson DA; Dickinson CJ; Wilken J; Barsh GS; Kent SB; Gantz I
    Mol Endocrinol; 1999 Jan; 13(1):148-55. PubMed ID: 9892020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of melanocortins in body weight regulation: opportunities for the treatment of obesity.
    MacNeil DJ; Howard AD; Guan X; Fong TM; Nargund RP; Bednarek MA; Goulet MT; Weinberg DH; Strack AM; Marsh DJ; Chen HY; Shen CP; Chen AS; Rosenblum CI; MacNeil T; Tota M; MacIntyre ED; Van der Ploeg LH
    Eur J Pharmacol; 2002 Aug; 450(1):93-109. PubMed ID: 12176114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of melanocortins in body weight regulation: opportunities for the treatment of obesity.
    MacNeil DJ; Howard AD; Guan X; Fong TM; Nargund RP; Bednarek MA; Goulet MT; Weinberg DH; Strack AM; Marsh DJ; Chen HY; Shen CP; Chen AS; Rosenblum CI; MacNeil T; Tota M; MacIntyre ED; Van der Ploeg LH
    Eur J Pharmacol; 2002 Apr; 440(2-3):141-57. PubMed ID: 12007532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the melanocortin system.
    Cortés R; Navarro S; Agulleiro MJ; Guillot R; García-Herranz V; Sánchez E; Cerdá-Reverter JM
    Gen Comp Endocrinol; 2014 Dec; 209():3-10. PubMed ID: 24768673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into G-protein-coupled receptor signaling from the melanocortin receptor system.
    Rana BK
    Mol Pharmacol; 2003 Jul; 64(1):1-4. PubMed ID: 12815154
    [No Abstract]   [Full Text] [Related]  

  • 16. Constitutive activity of neural melanocortin receptors.
    Tao YX; Huang H; Wang ZQ; Yang F; Williams JN; Nikiforovich GV
    Methods Enzymol; 2010; 484():267-79. PubMed ID: 21036237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of recombinant agouti-signaling protein on melanocortin action.
    Yang YK; Ollmann MM; Wilson BD; Dickinson C; Yamada T; Barsh GS; Gantz I
    Mol Endocrinol; 1997 Mar; 11(3):274-80. PubMed ID: 9058374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of central melanocortin signaling in eating disorders.
    Lu XY
    Psychopharmacol Bull; 2001; 35(4):45-65. PubMed ID: 12397856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New aspects on the melanocortins and their receptors.
    Wikberg JE; Muceniece R; Mandrika I; Prusis P; Lindblom J; Post C; Skottner A
    Pharmacol Res; 2000 Nov; 42(5):393-420. PubMed ID: 11023702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pharmacology of Agouti protein in vitro and in vivo.
    Barsh GS; Ollmann MM; Wilson BD; Miller KA; Gunn TM
    Ann N Y Acad Sci; 1999 Oct; 885():143-52. PubMed ID: 10816647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.